1. Home
  2. NAII vs GANX Comparison

NAII vs GANX Comparison

Compare NAII & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAII
  • GANX
  • Stock Information
  • Founded
  • NAII 1980
  • GANX 2017
  • Country
  • NAII United States
  • GANX United States
  • Employees
  • NAII N/A
  • GANX N/A
  • Industry
  • NAII Medicinal Chemicals and Botanical Products
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAII Health Care
  • GANX Health Care
  • Exchange
  • NAII Nasdaq
  • GANX Nasdaq
  • Market Cap
  • NAII 35.3M
  • GANX 31.5M
  • IPO Year
  • NAII 1987
  • GANX 2021
  • Fundamental
  • Price
  • NAII $5.80
  • GANX $1.38
  • Analyst Decision
  • NAII
  • GANX Strong Buy
  • Analyst Count
  • NAII 0
  • GANX 4
  • Target Price
  • NAII N/A
  • GANX $8.25
  • AVG Volume (30 Days)
  • NAII 4.5K
  • GANX 555.7K
  • Earning Date
  • NAII 05-14-2024
  • GANX 08-08-2024
  • Dividend Yield
  • NAII N/A
  • GANX N/A
  • EPS Growth
  • NAII N/A
  • GANX N/A
  • EPS
  • NAII N/A
  • GANX N/A
  • Revenue
  • NAII $120,201,000.00
  • GANX N/A
  • Revenue This Year
  • NAII N/A
  • GANX $1,009.10
  • Revenue Next Year
  • NAII N/A
  • GANX N/A
  • P/E Ratio
  • NAII N/A
  • GANX N/A
  • Revenue Growth
  • NAII N/A
  • GANX N/A
  • 52 Week Low
  • NAII $5.06
  • GANX $1.11
  • 52 Week High
  • NAII $7.62
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • NAII 42.28
  • GANX 42.17
  • Support Level
  • NAII $5.63
  • GANX $1.11
  • Resistance Level
  • NAII $5.88
  • GANX $1.40
  • Average True Range (ATR)
  • NAII 0.20
  • GANX 0.09
  • MACD
  • NAII -0.02
  • GANX 0.06
  • Stochastic Oscillator
  • NAII 39.42
  • GANX 93.10

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: